Vol. 2 No. 6 (2022): June
Reimbursement Reviews

Tralokinumab (Adtralza)

Published June 20, 2022

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses tralokinumab (Adtralza), solution for subcutaneous injection, 150 mg single-use pre-filled syringe (150 mg per 1 mL).
  • Indication: For the treatment of moderate to severe atopic dermatitis in adult patients whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable; Tralokinumab can be used with or without topical corticosteroids.